0.8698

4.42% -0.0402

After Hours: .8699 0.000100 +0.01%

Psyence Biomedical Ltd (PBM)

Overview News Price History Discussions Forecast

Psyence Biomedical Ltd stock is currently priced at $0.8698, with a 24-hour trading volume of 58,169. It has seen a -4.42% decreased in the last 24 hours and a +27.52% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.8877 pivot point. If it approaches the $0.8654 support level, significant changes may occur.

Previous Close:

$0.91

Open:

$0.91

24h Volume:

58,169

Market Cap:

$11.65M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-13.02%

1M Performance:

+27.52%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1D Range:

$0.834

$0.913

52W Range:

$0.5135

$4.31

Psyence Biomedical Ltd Stock (PBM) Company Profile

Name

Psyence Biomedical Ltd

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

PBM's Discussions on Twitter

Psyence Biomedical Ltd Stock (PBM) Latest News

Psyence Biomed participates in the AGP Virtual Healthcare Company Showcase - Fior Reports

Fior Reports

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase - GlobeNewswire

GlobeNewswire

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

GlobeNewswire Inc.

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

GlobeNewswire Inc.

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

GlobeNewswire Inc.

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

GlobeNewswire Inc.

Psyence Biomedical Ltd Stock (PBM) Financials Data

There is no financial data for Psyence Biomedical Ltd (PBM). Check out other stocks for more information.

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.